Systemic Therapy for Rare Tumours of the Skin and Soft Tissue Tumour
The role of systemic therapy in the management of soft tissue sarcoma and rare tumours of the skin is still extremely important. Even if the principal therapeutic approach in the localised disease is represented by surgery, in the metastatic setting, the role of surgery is still poorly defined, and a systemic approach becomes mandatory. Furthermore, the possible use of systemic therapies both in the adjuvant setting, with the aim of consolidating the results obtained through surgery, and in the neoadjuvant setting, in order to optimise the local control of the disease, has been recently assessed.
For years, standard chemotherapy has represented the only systemic approach available in the treatment of soft tissue sarcoma and rare tumours of the skin: however, given the poor results obtained up today, newer compounds and target therapies are currently under active investigation.
KeywordsOverall Survival Soft Tissue Sarcoma Synovial Sarcoma Merkel Cell Carcinoma Ewing Sarcoma
Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.
Treatment given as a first step to shrink a tumour before the main treatment, which is usually surgery, is given.
The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. The overall survival rate is often stated as a 5-year survival rate, which is the percentage of people in a study or treatment group who are alive 5 years after diagnosis or treatment.
The length of time during and after treatment in which a patient is living with a disease that does not get worse.
Non-epithelial extraskeletal tissue, including muscle, fat and fibrous supporting structures, arising mainly from embryonic mesoderm, with some neuroectodermal contribution.
- 1.Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (editors). SEER Cancer Statistics Review, 1975–2005. Bethesda: National Cancer Institute; 2008. http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site.
- 5.Rutgers EJ, Kroon BB, Albus-Lutter CE, Gortzak E. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol. 1997;18:241–8.Google Scholar
- 6.Patel KU, Szabo SS, Hernandez VS, Prieto VG, Abruzzo LV, Lazar AJ, et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays, Hum Pathol. 2008;39(2):184–93.PubMedCrossRefGoogle Scholar
- 10.Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007;25(21):3144–50.PubMedCrossRefGoogle Scholar
- 13.Le Cesne A, Van Glabbeke M, Woll PJ, Bramwell VH, Casali PG, Hoekstra HJ, Reichardt P, Hogendoorn PC, Hohenberger P, Blay JY. The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): Pooled analysis of the two STBSG-EORTC phase III clinical trials. J Clin Oncol (ASCO Annual Meeting). 2008;20(15S):10525.Google Scholar
- 15.Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37(7):870–7.PubMedCrossRefGoogle Scholar
- 21.Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25(19):2755–63.PubMedCrossRefGoogle Scholar
- 24.Poulsen M, Rischin D, Walpole E, Harvey J, Macintosh J, Ainslie J, et al. Analysis of toxicity of Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study. Int J Radiat Oncol Biol Phys. 2001;51(1):156–63.PubMedCrossRefGoogle Scholar
- 27.McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005;23(4):866–73.PubMedCrossRefGoogle Scholar
- 34.Chawla SP. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol (ASCO Annual Meeting). 2011;29(15 suppl):10005 (abstract).Google Scholar
- 35.Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer-soft Tissue and Bone Sarcoma Group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126–32.PubMedCrossRefGoogle Scholar
- 37.Levy AP, Pauloski N, Braun D, et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43–9006). Proc Am Assoc Cancer Res. 2006;47:213–4.Google Scholar
- 39.Leahy M, Ray-Coquard I, Verweij J, Le Cesne A, Duffaud F, Hogendoorn PC, et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2007;43(2):308–15.PubMedCrossRefGoogle Scholar
- 40.Krasagakis K, Fragiadaki I, Metaxari M, Krüger-Krasagakis S, Tzanakakis GN, Stathopoulos EN, et al. KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of Merkel cell carcinoma in vitro. J Cell Physiol. 2011;226(4):1099–109. doi: 10.1002/jcp.22431.PubMedCrossRefGoogle Scholar